4 Interactions found for:
Drug Interactions
No drug interactions were found for selected drugs: tizanidine, Vitamin B12.
This does not necessarily mean no interactions exist. Always consult your healthcare provider.
Drug and Food Interactions
No food interactions were found for selected drugs: tizanidine, Vitamin B12.
This does not necessarily mean no interactions exist. Always consult your healthcare provider.
Drug and Pregnancy Interactions
Minor
Vitamin B12
+ Pregnancy
The following applies to the ingredients: Cyanocobalamin (found in Vitamin B12)
Professional Content
This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. (AU)
AU TGA pregnancy category: Exempt
US FDA pregnancy category: C
Comments:
-Vitamin B12 needs are increased in pregnancy.
-Megaloblastic anemia of pregnancy is usually due to folic acid deficiency.
-Do not use for megaloblastic anemia of pregnancy due to folic acid deficiency.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Allen LH "Multiple micronutrients in pregnancy and lactation: an overview." Am J Clin Nutr 81(S) (2005): 1206S-12S
- "Product Information. Cyanocobalamin (cyanocobalamin)." West Ward Pharmaceutical Corporation (2017):
Minor
Tizanidine
+ Pregnancy
The following applies to the ingredients: Tizanidine
Professional Content
Benefit should outweigh risk
US FDA pregnancy category: C
Teratogenicity was not shown in animal studies in rats and rabbits. At doses up to 8 times the maximum recommended human dose, increased gestation duration was observed in rats. Pre and prenatal and postnatal pup loss and developmental retardation occurred in rats and rabbits and post-implantation loss was increased in rabbits at doses of 1 mg/kg or more. There are no controlled studies in pregnant women.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
References
- "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics PROD (2001):
Drug and Breastfeeding Interactions
Major
Tizanidine
+ Breastfeeding
The following applies to the ingredients: Tizanidine
Professional Content
Safety has not been established
Excreted into human milk: Unknown
Excreted into animal milk: Yes
Comments: If used, monitor infant for toxicity such as sedation, hypotension, and hallucinations.
As a lipid soluble drug, it might be expected to pass into breast milk.
References
- "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Minor
Vitamin B12
+ Breastfeeding
The following applies to the ingredients: Cyanocobalamin (found in Vitamin B12)
Professional Content
Use is not recommended; benefit to mother should outweigh risk to the infant. (AU)
Excreted into human milk: Yes
Comments:
-Vitamin B12 needs are increased in lactation.
-Deficiency has been seen in breast fed children of vegetarian mothers, even with no symptoms of maternal deficiency.
-Four micrograms daily of B12 are recommended during lactation.
References
- Ehrlich A, Koch T, Amin B, et al. "Development and reliability testing of a standardized questionnaire to assess psoriasis phenotype." J Am Acad Dermatol 54 (2006): 987.e1-14
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Nascobal (cyanocobalamin)." Par Pharmaceutical Inc (2017):
Therapeutic Duplication Warnings
No warnings were found for your selected drugs.Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Switch to: Professional Interactions
Drug Interaction Classification | |
---|---|
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication. |
|
Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Unknown | No interaction information available. |
Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.